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 Th e introduction of recombinant human 
erythropoietin in 1989 for the treatment 
of the anemia of chronic kidney failure 
was one of the most important events in 
the biotechnology era, ushering in its path 
a large number of other recombinant pro-
teins in the treatment of human disease. 
By 2006, worldwide sales for erythropoi-
esis-stimulating agents (ESAs) had 
reached more than US $ 10 billion, and the 
two ESAs available in the United States —
 epoetin and darbepoetin — became the 
top sources of Medicare drug expendi-
ture. In 2006, the average dose of ESA 
used in dialysis patients in the United 
States was more than 7500 units per sin-
gle administration, compared with 
approximately 3000 units in 1991. 1 Before 
2006,  ‘ more is better ’ was the prevailing 
mantra in the nephrology community, for 
a variety of reasons, profi t perhaps being 
one of them. 2 
 Th e rise in ESA use did not come with-
out its problems. In 1998, safety warnings 
were added to the epoetin label following 
the publication of the Normal Hematocrit 
study, 3 and then in 2007, following 
the publication of the Correction of 
 Hemoglobin and Outcomes in Renal 
 Insuffi  ciency (CHOIR) 4 and Cardiovas-
cular Risk Reduction by Early Anemia 
Treatment with Epoetin Beta (CREATE) 5 
studies, a black box warning was inserted. 
Data from ESA treatment trials in patients 
with cancer-associated anemia, 6 critically 
ill patients, 7 and otherwise healthy 
patients undergoing spine surgery 8 have 
all pointed to increased risk with the use 
of ESAs to correct anemia. Indeed, most 
recently in the Reduction of Infarct 
Expansion and Ventricular Remodeling 
With Erythropoietin Aft er Large Myocar-
dial Infarction (REVEAL) trial, 9 the acute 
administration of a single high-dose intra-
venous bolus of epoetin alfa in patients 
with acute ST-segment elevation myocar-
dial infarction who had successful 
reperfusion with primary or rescue per-
cutaneous coronary intervention did not 
reduce infarct size but was instead associ-
ated with higher rates of adverse cardio-
vascular events. Furthermore, in a 
prespecifi ed analysis of patients aged 70 
years or older, exposure to epoetin alfa 
signifi cantly increased infarct size. Th e 
Trial to Reduce Cardiovascular Events 
With Aranesp Th erapy (TREAT) study, 10 
using a placebo-controlled double-blind 
design, has raised further safety concerns 
about the use of ESAs in the treatment of 
anemia in diabetic patients with chronic 
kidney disease (CKD). TREAT demon-
strated a twofold higher risk of stroke, 
with an even higher risk of stroke among 
those with a prior history of stroke. 
TREAT also showed increased risk of 
venous thromboembolism and cancer-
related deaths. Th ese risks came without 
apparent benefi t, because improvement in 
quality of life with darbepoetin therapy 
was minimal. 
 Since the black box warning by the US 
Food and Drug Administration (FDA), 
sales of ESAs have declined. With bun-
dling, it is likely that the sales of ESAs will 
fall even further. Most nephrologists have 
a feeling of uncertainty when prescribing 
ESAs, and now there is a fi nancial incentive 
in the United States to use lower doses. A 
recent preliminary fi nding by the Centers 
for Medicare and Medicaid Ser vices point-
edly implied that there is no clinical ben-
efi t in using ESAs to treat CKD anemia. 11 
To be sure, no one wants to return to the 
pre-ESA era, when end-stage renal disease 
patients were managed with repeated 
blood transfusions, iron therapy, anabolic 
steroids, and other maneuvers. There 
appears to be a benefi t of ESA therapy in 
preventing the need for blood transfusions, 
particularly in potential kidney recipients. 
As well, notwithstanding confl icting data 
from randomized trials, correcting anemia 
from very low hemoglobin (Hb) concen-
trations to levels greater than 9  g / dl prob-
ably does reduce fatigue, at least in some 
patients. However, the trials showing 
increased risk; the repeated regulatory 
warnings, including a black box on the 
ESA label; and the erosion of confi dence in 
guidelines have given pause to nephrolo-
gists in treating CKD anemia. 
 Cotter and colleagues (Zhang  et al. , 12 
this issue) now report the results of a large 
observational analysis of 35,593 elderly 
Medicare patients on hemodialysis. Of 
these, they selected 19,034 diabetics (53 % ) 
to examine the hypothesis that exposure 
to higher dosages of ESA is associated 
with increased risk. In order to address 
the potential eff ects of time-dependent 
confounding by indication, Cotter and 
colleagues used inverse probability 
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weighting (an approach termed marginal 
structural modeling, or MSM). Th e main 
finding in this study is that diabetic 
patients exposed to higher dosages of ESA 
had a higher rate of all-cause mortality 
and the composite of death and cardiovas-
cular events (hazard ratio (95 % confi dence 
interval) was 1.32 (1.11 – 1.58) for all-cause 
mortality and 1.26 (1.07 – 1.50) for the 
composite of death and cardiovascular 
outc ome s  i n  p at i e nt s  e x p o s e d 
to   >  40,000  U / wk compared with 20,000 –
 30,000  U / wk ESA). 
 What are the key concepts that one 
should keep in mind when reading this 
study? First, it is an observational analysis. 
Consequently, the control of confounding 
is a fundamental problem in both analysis 
and interpretation. (A confounder is 
defi ned as a variable associated with the 
occurrence of the outcome event and the 
treatment.) Standard regression models 
and Mantel – Haenszel methods have been 
rightly criticized for their inability to 
exclude confounding. However, MSM 
does not completely exclude the eff ect of 
confounding either. Furthermore, while 
MSMs are designed to assess for causality 
in longitudinal data sets, these models are 
limited to the study of non-dynamic treat-
ment regimes (regimes that are  ‘ fi xed in 
advance ’ ) — for example, treatment with a 
fixed dose of a drug throughout preg-
nancy regardless of intervening events 
before delivery. Dynamic regimes, such as 
the treatment of CKD anemia, require 
structural nested models or  G -estimation 
(varying doses of epoetin are given in the 
context of changing Hb levels over time). 
In Cotter and colleagues ’ paper, 12 residual 
confounding most likely remains present, 
because certain variables are not recorded 
in the US Renal Data System (USRDS) 
database. Th e other limitation is the qual-
ity of the USRDS data set itself. Essentially, 
USRDS is administrative in nature, and its 
vagaries and inaccuracies have already 
been recognized. In Cotter and colleagues ’ 
study 12 the reporting of diabetes status, or 
of comorbidities such as cardiovascular 
disease, or the use of diff erent medica-
tions, is likely to be of limited accuracy. 
 Several prior observational analyses 
have also examined whether there is a 
relationship between ESA dose and 
adverse outcome in CKD patients. In gen-
eral, the crude relationship between ESA 
dose and outcome is one of increased risk 
with exposure to greater ESA dose. How-
ever, diff erent analytical models have gen-
erated confl icting results. Bradbury and 
co-workers from Amgen explored a Fre-
senius North America cohort. 13 They 
reported increased crude mortality risk 
with increasing epoetin dose (hazard ratio 
(HR), 1.31 per log unit increase; 95 % con-
fi dence interval (CI), 1.26 – 1.36), but with 
adjustment for baseline patient character-
istics, or when lagged time-dependent 
analyses were performed, the diff erences 
became non-signifi cant (HR, 1.01; 95 % 
CI, 0.99 – 1.03). In another analysis, using 
MSM, Bradbury and colleagues reported 
no association between high ESA dose 
and adverse outcome. 14 Cotter ’ s group in 
a prior study, using the USRDS data set 
and methodology similar to that of the 
current paper (inverse probability weight-
ing), were unable to demonstrate an asso-
ciation between cumulative average 
epoetin dosage and survival. However, 
this analysis was restricted to elderly 
hemodialysis patients. 
 Landmark analysis has been used to 
examine the relationship between ESA 
exposure and outcome. In the landmark 
method, the bias favoring the responders 
(in this case, response to ESA) associated 
with a time-dependent variable is attenu-
ated. Szczech  et al. , 15 using the CHOIR 
database, performed both unadjusted 
and adjusted analyses at the 4- and 
9-month landmarks to examine the rela-
tionship between ESA dose and outcome. 
In the unadjusted analysis, the inability 
to achieve a target Hb and high-dose 
epoetin were each signifi cantly associated 
with increased risk of a primary end 
point (death, myocardial infarction, con-
gestive heart failure, or stroke). In 
adjusted models, at 4 months, high-dose 
epoetin was associated with a signifi-
cantly increased hazard of a primary end 
point (57 % increased hazard of the pri-
mary end point: HR, 1.57; CI, 1.04 – 2.36; 
 P  =  0.03). Similar results were seen in the 
9-month analysis. 
 Where does this leave us? If one believes 
that the adverse risk observed in the ran-
domized trials solely refl ects the targeting 
of too high a Hb concentration, and that 
the recent observational analyses evaluat-
ing the eff ects of high ESA dose are inher-
ently limited, then the focus should be on 
the Hb concentration and targeting an 
arbitrarily set Hb range. Indeed, the latest 
FDA drug safety communication 
announced 27 June 2011, recommends 
that there should be paradigm shift  away 
from a focus on Hb range to one of indi-
vidualizing anemia management and 
using the lowest possible dose of ESA. For 
dialysis patients, the advisory recom-
mends either interruption or reduction of 
ESA dose if the Hb rises beyond11  g / dl. 
Until recently, dialysis providers favored 
this narrow approach of focusing on the 
Hb without much attention to using the 
lowest possible ESA dose — perhaps a case 
of Upton Sinclair ’ s maxim,  ‘ It is diffi  cult to 
get a man to understand something, when 
his salary depends upon his not under-
standing it. ’ While it is true that the rand-
omized controlled trials in anemia were 
solely designed to test the eff ect of target-
ing a specifi c Hb on outcomes, rather than 
a relationship between ESA dose and out-
come, many observational analyses 
including secondary analyses of the rand-
omized trials collectively suggest that the 
problem is not the achieving of a high Hb 
concentration but the  ‘ act of targeting a 
higher Hb concentration. ’ In fact, recent 
data 16 demonstrate superior outcomes in 
dialysis patients who have naturally occur-
ring higher Hb concentrations. Th is  ‘ act of 
targeting a higher Hb concentration, ’ espe-
cially the use of very high ESA doses in 
patients who are hyporesponsive to ESAs, 
seems to explain the higher adverse risk. 
 On the other hand, if one views the evi-
dence as suggesting that the use of exces-
sive dosages of ESA better explains the 
increased adverse risk, then the focus 
should be on ESA dose. Important ques-
tions to ask in managing your patient 
would be: does the individualized risk –
 reward ratio favor treating with an ESA? 
Second, determine the patient ’ s transfu-
sion trigger. It is likely to be unique to 
each patient, but probably around 9   g / dl. 
For example, for some patients, particu-
larly those who are young it may be 8   g / dl 
or even lower; for older patients or those 
with co-morbidities, it might be 9 or 
10.0   g / dl. And third, if treatment is neces-
sary, what dosage of ESA should I pre-
scribe? One conclusion seems clear: 
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prescribe the lowest dose of ESA to 
improve symptoms, rather than aiming 
for an arbitrarily set 10 – 12  g / dl Hb target. 
Th is is the approach that the FDA in its 
changes to the ESA label, and CMS in 
their change to the Quality Improvement 
Program (QIP) are now recommending 
and in patients who are not on dialysis, 
treatment may not even be necessary. 
Another important conclusion is that, in 
patients who have a history of cancer, or 
in those with a history of stroke, ESA 
therapy should be avoided if possible and 
blood transfusion be used as the mainstay 
of treatment. If ESAs are necessary, then 
very low ESA dosages should be used. 
Seliger  et al. , 17 examining national Veter-
ans Aff airs data with a case-control study 
design, report a signifi cant association 
between incident ESA use and acute 
stroke in CKD patients (odds ratio, 1.30). 
Interestingly, Seliger  et al. also report a 
signifi cant interaction between ESA use 
and cancer, with greater odds of stroke 
among ESA-treated cancer patients (odds 
ratio, 1.85), but not in ESA-treated patients 
without cancer (odds ratio, 1.07). What 
about the problem of sensitizing patients 
who are potential kidney transplant recip-
ients or the goal of preventing blood 
transfusions? In patients eligible for kid-
ney transplantation, treatment with an 
ESA to prevent blood transfusion seems 
reasonable. However, in patients who have 
a history of cancer or those with a history 
of stroke, transplant candidacy is not 
an issue. 
 Some have argued for a  status quo in the 
current approach to treating anemia in 
CKD patients: keep the Hb target at 
10 – 12  g / dl, and dose with ESA as needed 
to accomplish this Hb target. Th is seems 
contradictory with respect to both the evi-
dence and our interests as physicians in 
fi rst doing no harm. 
 Where do we need to go? What we need 
is a large, well-designed, adequately pow-
ered randomized controlled study exam-
ining the effect of ESA dose on hard 
outcomes. As I have written before, the 
FDA has the statutory authority to 
demand such a trial. If the FDA cannot 
muster the courage to demand such a trial, 
then Congress needs to press it to do so. 
In Europe, an Italian trial funded by the 
European Union, termed the Clinical 
Evaluation of the Dose of Erythropoietins 
(CEDOSE) trial, could provide an answer. 
In the study design of the CEDOSE trial, 
patients will be randomized to a high fi xed 
dose of ESA (18,000  U / wk) versus a low 
fi xed dose of ESA (4000  U / wk) with dose 
adjustment if the Hb level falls outside the 
9.5 – 12.5  g / dl range. Evaluation of hard 
outcomes (such as death and cardiovascu-
lar mortality) is planned. Hopefully, the 
CEDOSE trail will provide the long-
awaited answer to the question: Is expos-
ing patients to ESAs harmful? 
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